Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioblastoma × tofacitinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Psoriasis 6 Lymphoma, Follicular 6 Bronchiolitis Obliterans Syndrome 6 Pruritus 4 Arthritis, Rheumatoid 3 Plaque, Amyloid 1 Myasthenia Gravis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Extranodal NK-T-Cell 1 Glioblastoma 1 Cholangiocarcinoma 1 Arthritis, Psoriatic 1 Adenocarcinoma 1

Interventions

Temozolomide 344 Radiotherapy 172 Bevacizumab 133 Radiation 66 Magnetic Resonance Spectroscopy 56 Lomustine 42 pembrolizumab 35 Irinotecan 35 Carmustine 35 Surgical Procedures, Operative 32 Nivolumab 26 Carboplatin 25 Radiosurgery 22 Specimen Handling 20 Erlotinib Hydrochloride 20 Chemotherapy, Adjuvant 20 Radiotherapy, Intensity-Modulated 18 Aminolevulinic Acid 18 Drug Therapy 17 Cyclophosphamide 16 sargramostim 15 O(6)-benzylguanine 13 Radiotherapy, Conformal 12 Granulocyte-Macrophage Colony-Stimulating Factor 12 Everolimus 12 Vorinostat 11 Sunitinib 11 Cilengitide 11 temsirolimus 10 poly ICLC 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05326464 2025-12-15

Tofacitinib in Recurrent GBM Patients

University of Texas Southwestern Medical Center

Phase 3 Active not recruiting

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡